Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

César Serrano; Adrián Mariño-Enríquez; Derrick L. Tao; Julia Ketzer; Grant Eilers; Meijun Zhu; Channing Yu; Aristotle M. Mannan; Brian P. Rubin; George D. Demetri; Chandrajit P. Raut; Ajia Presnell; Arin McKinley; Michael C. Heinrich; Jeffrey T. Czaplinski; Ewa Sicinska; Sebastian Bauer; Suzanne George; Jonathan A. Fletcher

doi:10.1038/s41416-019-0487-5

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

César Serrano, Adrián Mariño-Enríquez, Derrick L. Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M. Mannan, Brian P. Rubin, George D. Demetri, Chandrajit P. Raut, Ajia Presnell, Arin McKinley, Michael C. Heinrich, Jeffrey T. Czaplinski, Ewa Sicinska, Sebastian Bauer, Suzanne George, Jonathan A. Fletcher

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

Original language	English (US)
Pages (from-to)	281
Number of pages	1
Journal	British Journal of Cancer
Volume	121
Issue number	3
DOIs	https://doi.org/10.1038/s41416-019-0487-5
State	Published - Jul 30 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s41416-019-0487-5

Fingerprint

Dive into the research topics of 'Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)'. Together they form a unique fingerprint.

Cite this

Serrano, C., Mariño-Enríquez, A., Tao, D. L., Ketzer, J., Eilers, G., Zhu, M., Yu, C., Mannan, A. M., Rubin, B. P., Demetri, G. D., Raut, C. P., Presnell, A., McKinley, A., Heinrich, M. C., Czaplinski, J. T., Sicinska, E., Bauer, S., George, S., & Fletcher, J. A. (2019). Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). British Journal of Cancer, 121(3), 281. https://doi.org/10.1038/s41416-019-0487-5

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). / Serrano, César; Mariño-Enríquez, Adrián; Tao, Derrick L. et al.
In: British Journal of Cancer, Vol. 121, No. 3, 30.07.2019, p. 281.

Research output: Contribution to journal › Comment/debate › peer-review

Serrano, C, Mariño-Enríquez, A, Tao, DL, Ketzer, J, Eilers, G, Zhu, M, Yu, C, Mannan, AM, Rubin, BP, Demetri, GD, Raut, CP, Presnell, A, McKinley, A, Heinrich, MC, Czaplinski, JT, Sicinska, E, Bauer, S, George, S & Fletcher, JA 2019, 'Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)', British Journal of Cancer, vol. 121, no. 3, pp. 281. https://doi.org/10.1038/s41416-019-0487-5

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M et al. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). British Journal of Cancer. 2019 Jul 30;121(3):281. doi: 10.1038/s41416-019-0487-5

Serrano, César ; Mariño-Enríquez, Adrián ; Tao, Derrick L. et al. / Correction : Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). In: British Journal of Cancer. 2019 ; Vol. 121, No. 3. pp. 281.

@article{9f3830cfd11749dfb82db50e94e0f89b,

title = "Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)",

abstract = "The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.",

author = "C{\'e}sar Serrano and Adri{\'a}n Mari{\~n}o-Enr{\'i}quez and Tao, {Derrick L.} and Julia Ketzer and Grant Eilers and Meijun Zhu and Channing Yu and Mannan, {Aristotle M.} and Rubin, {Brian P.} and Demetri, {George D.} and Raut, {Chandrajit P.} and Ajia Presnell and Arin McKinley and Heinrich, {Michael C.} and Czaplinski, {Jeffrey T.} and Ewa Sicinska and Sebastian Bauer and Suzanne George and Fletcher, {Jonathan A.}",

note = "Publisher Copyright: {\textcopyright} 2019, Cancer Research UK.",

year = "2019",

month = jul,

day = "30",

doi = "10.1038/s41416-019-0487-5",

language = "English (US)",

volume = "121",

pages = "281",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Correction

T2 - Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

AU - Serrano, César

AU - Mariño-Enríquez, Adrián

AU - Tao, Derrick L.

AU - Ketzer, Julia

AU - Eilers, Grant

AU - Zhu, Meijun

AU - Yu, Channing

AU - Mannan, Aristotle M.

AU - Rubin, Brian P.

AU - Demetri, George D.

AU - Raut, Chandrajit P.

AU - Presnell, Ajia

AU - McKinley, Arin

AU - Heinrich, Michael C.

AU - Czaplinski, Jeffrey T.

AU - Sicinska, Ewa

AU - Bauer, Sebastian

AU - George, Suzanne

AU - Fletcher, Jonathan A.

PY - 2019/7/30

Y1 - 2019/7/30

N2 - The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

AB - The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

UR - http://www.scopus.com/inward/record.url?scp=85066155358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066155358&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0487-5

DO - 10.1038/s41416-019-0487-5

M3 - Comment/debate

C2 - 31123346

AN - SCOPUS:85066155358

SN - 0007-0920

VL - 121

SP - 281

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this